Development of activated natural killer (NK) cells mediated immunotherapy in cancer
| ISRCTN | ISRCTN79498301 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN79498301 |
| Protocol serial number | N/A |
| Sponsor | Sookmyung Women's University (Korea, South) |
| Funder | Korea Health Industry Development Institute (KHIDI) (ref: A080363) |
- Submission date
- 15/07/2008
- Registration date
- 08/08/2008
- Last edited
- 16/08/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Miss Hareum Lee
Scientific
Scientific
Department of Life Sciences
Sookmyung Women's University
Hyochangwon-gil 52
Yongsan-gu
Seoul
140-742
Korea, South
Study information
| Primary study design | Observational |
|---|---|
| Study design | Single-centre, observational study |
| Secondary study design | Other |
| Study type | Participant information sheet |
| Scientific title | Research for the effect of biological response modifiers (BRMs) on natural killer (NK) cell cytotoxicity |
| Study objectives | Natural killer (NK) cells play an important role in innate immune response by destroying tumours and virus-infected cells without prior stimulation. Because of their attractive features, the application of NK cell-based immunotherapy has been extended to cancer treatment. This study investigates the function of biological response modifiers (BRMs) on NK cell cytotoxicity and the effect of NK cell mediated immunotherapy in cancer. |
| Ethics approval(s) | Samsung Medical Centre Institutional Review Board. Date of approval: 18/03/2008 (ref: 2008-03-038) |
| Health condition(s) or problem(s) studied | Immunotherapy in cancer |
| Intervention | A blood sample will be obtained from each participant. A variety of BRMs (small synthetic peptides, interleukins, natural extracts) will be tested on the blood samples to measure their effect on NK cell cytotoxicity. This will be measured using established assays such as carboxyfluorescein diacetate succinimidylester (CFSE). The BRMs that show high levels of NK cell cytotoxicity will have the potential for use in cancer treatment. Contact details of Principal Investigator: Dr Daeho Cho Department of Life Sciences Sookmyung Women's University Hyochangwon-gil 52 Yongsan-gu Seoul, 140-742 Korea, South Tel: +82 2 710 9416 Fax: +82 2 6359 6789 Email: cdhkor@sm.ac.kr |
| Intervention type | Other |
| Primary outcome measure(s) |
1. To find BRMs that lead to the highest levels of NK cell cytotoxicity in the treated blood samples |
| Key secondary outcome measure(s) |
Gene expression profiles associated with peripheral blood lymphocyte (PBL) cytotoxicity and related mechanisms in the blood samples. |
| Completion date | 30/04/2010 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 30 |
| Key inclusion criteria | 1. Healthy volunteers aged 18 years or older, both males and females 2. Written informed consent |
| Key exclusion criteria | 1. Aged less than 18 years 2. Those who do not speak Korean |
| Date of first enrolment | 01/05/2008 |
| Date of final enrolment | 30/04/2010 |
Locations
Countries of recruitment
- Korea, South
Study participating centre
Department of Life Sciences
Seoul
140-742
Korea, South
140-742
Korea, South
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
